-GAD Diagnosis Increases Healthcare Costs and
Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher
Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden
in the US Conducted by MindMed; Company is Investigating New
Treatments for GAD and Other Brain Health Disorders-
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ:
MNMD) (the “Company” or “MindMed”), a clinical stage
biopharmaceutical company developing novel product candidates to
treat brain health disorders, today presented new studies
highlighting the significant impact of GAD in the US at ISPOR 2024,
the leading global conference for health economics and outcomes
research (HEOR) being held this week in Atlanta.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240509733055/en/
Figure 1. Work Productivity: Absenteeism,
presenteeism, overall work productivity loss and activity
impairment: GAD by symptom severity vs. controls. Note: Groups that
were statistically significant at p0.05, 2-tailed, compared with
controls are marked with asterisks. Absenteeism, Presenteeism, and
Overall work impairment were only applicable to those indicating
they were currently working for pay. Absenteeism was not calculated
for those who worked 0 hours and missed 0 hours in the last 7 days,
and presenteeism was only asked among those who worked >0 hours
in the last 7 days. (Abbreviations: GAD: generalized anxiety
disorder.) (Graphic: Business Wire)
Three studies examined the impact of GAD on healthcare
utilization and costs, workplace productivity, and healthcare
quality of life (HC QOL). All three studies demonstrated that the
economic and societal impact of GAD is substantial, gets worse when
anxiety symptoms are more severe, and is more significant when GAD
is present but undiagnosed.
“These studies clearly demonstrate that the burden of GAD on the
US healthcare system, employers, and people living with GAD is
enormous. We continue to discover evidence that the impact of GAD
has been underappreciated and that people living with this disorder
are underserved,” said Daniel R. Karlin, MD, MA, Chief Medical
Officer of MindMed and senior author of these studies. “We
undertook these studies as part of our commitment to highlight the
scale of the anxiety crisis and our mission to address this burden.
The results of these in-depth analyses speak for themselves.”
The studies were conducted using data from the 2022 National
Health and Wellness Survey (NHWS; N=75,261). The NHWS is an annual
internet-based survey; all data are self-reported. Recruitment is
designed to represent the general US adult population in terms of
age, race, ethnicity and gender distribution. Participants were
requested to use the clinically validated GAD-7 screening tool as
recently recommended by the US Preventive Services Task Force
(USPSTF).
Three studies were presented at ISPOR 24:
- Work Productivity and Activity
Impairment Associated with Generalized Anxiety Disorder among
Adults in the United States - Health Care
Resource Use Associated with Generalized Anxiety Disorder among
Adults in the United States -
Health-related Quality of Life Associated with
Generalized Anxiety Disorder among Adults in the United States
Key Findings from MindMed HEOR Studies
Work Productivity (see Figure 1)
- Compared with controls (8.0%, 95% CI: 7.6%-8.4%),
absenteeism was statistically significantly higher among the
severe Diagnosed GAD group (11.4%, 95% CI: 8.4%-15.5%) (p=0.03) and
increased as severity worsened among adults diagnosed with GAD
(none: 6.0%, 95% CI: 4.5%-8.0%, mild: 7.9%, 95% CI: 6.2%-10.1%,
moderate: 9.6%, 95% CI: 7.3%-12.8%, severe: 11.4%, 95% CI:
8.4%-15.5%).
- Compared with controls (19.3%, 95% CI: 18.8%-19.7%),
presenteeism was significantly higher among the mild,
moderate, and severe Diagnosed GAD groups (22.6%-26.3%) and
increased as severity worsened among adults diagnosed with GAD
(none: 15.0%, 95% CI: 13.0%, 17.4%, mild: 22.6%, 95% CI:
20.1%-25.6%, moderate: 24.1%, 95% CI: 20.8%-27.8%, severe: 26.3%,
95% CI: 22.5%-30.7%).
- Compared with controls (22.5%, 95% CI: 22.0%-22.9%), overall
work productivity impairment was statistically significantly
higher among the mild, moderate, and severe Diagnosed GAD groups
(26.1%-30.0%) and increased as severity worsened among adults
diagnosed with GAD (none: 17.7%, 95% CI: 15.4%-20.3%, mild: 26.1%,
95% CI: 23.3%-29.3%, moderate: 27.8%, 95% CI: 24.3%-31.9%, severe:
30.0%, 95% CI: 25.9%-34.7%).
Healthcare Resource Use (HCRU) (see Figure 2)
- Diagnosed GAD patients had an adjusted average of 3.1 HCP
visits, 0.31 ER visits, and 0.19 hospitalizations within the past 6
months.
- Undiagnosed people who screened positive for GAD (using the
USPSTF-recommended GAD-7 screening tool) had an adjusted average of
2.2 HCP visits, 0.51 ER visits, and 0.36 hospitalizations within
the past 6 months.
- Compared with the diagnosed GAD group, the undiagnosed GAD
group had significantly lower rates of HCP visits (IDR: 0.71, 95%
CI: 0.66-0.77, p<0.01).
- However, those with undiagnosed GAD were 1.64 times more likely
to have an ER visit (95% CI:1.42-1.90) and 1.95 times more likely
to have a hospitalization (95% CI: 1.59-2.40) than the diagnosed
GAD group, suggesting significantly greater HCRU among the
undiagnosed group (both p<0.01).
- Those with no GAD diagnosis who screened negative for GAD
(No-GAD) had an adjusted average of 2.0 HCP visits, 0.26 ER visits,
and 0.18 hospitalizations within the past 6 months.
- Compared with the diagnosed GAD group, the no-GAD group had
significantly lower rates of HCP visits (IDR: 0.64, 95% CI:
0.59-0.68, p<0.01).
- Compared with the diagnosed GAD group, the no-GAD group had
significantly lower rates of ER visits (IDR: 0.84, 95% CI:
0.73-0.96, p=0.01) and similar hospitalization rates (IDR: 0.97,
95% CI: 0.80-1.19).
Health-Related Quality of Life (HR QOL) (see Figure 3)
- Compared with controls (45.3, 95%CI: 45.2-45.4), adjusted
Global Health Composite (GHC) scores were significantly lower among
the mild, moderate, and severe Diagnosed GAD groups
(35.0-41.5).
- Adjusted GHC scores decreased as severity worsened among adults
diagnosed with GAD (mild: 41.5, 95% CI: 41.0-42.0, moderate: 38.3,
95% CI: 37.8-38.9, and severe GAD: 35.0, 95% CI: 34.4-35.6).
- A similar trend was observed for Mental Health Composite (MHC)
and Physical Health Composite (PHC) scores.
- The magnitude of the difference in MHC scores was larger than
the difference observed in PHC scores, suggesting a greater impact
of GAD symptom severity on mental health functioning than physical
health functioning.
“From my perspective, one key takeaway from our research is the
significant and increasing impact of GAD on work productivity,
which should concern employers and payers,” according to the lead
author of the studies, Phong Duong, PharmD, Vice President of
Global Market Access, Health Economics and Outcomes Research at
MindMed. “The other key finding was that people with undiagnosed
GAD may actually cost more to manage in terms of overall healthcare
resource utilization than those who have been diagnosed, which
strongly supports screening the general population for GAD using
the clinically validated GAD-7 screening tool as recently
recommended by the US Preventive Services Task Force (USPSTF).”
About Generalized Anxiety Disorder (GAD)
GAD is a common condition associated with significant impairment
that adversely affects millions of people. GAD results in fear,
persistent anxiety, and a constant feeling of being overwhelmed. It
is characterized by excessive, persistent, and unrealistic worry
about everyday things. Approximately 10% of U.S. adults,
representing around 20 million people, currently suffer from GAD.
This underdiagnosed and underserved indication is associated with
significant impairment, less accomplishment at work and reduced
labor force participation. Despite the significant personal and
societal burden of GAD, there has been little innovation in the
treatment of GAD in the past several decades, with the last new
drug approval occurring in 2007.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding the
prevalence of undiagnosed GAD patients; the cost of treating GAD
patients; the potential impact of GAD on productivity; and the
potential benefits of the Company’s product candidates. There can
be no guarantees regarding the results of the potential Phase 3
clinical trial or that, following any such trial, MM120 will
receive the necessary regulatory approvals. There are numerous
risks and uncertainties that could cause actual results and the
Company’s plans and objectives to differ materially from those
expressed in the forward-looking information, including history of
negative cash flows; limited operating history; incurrence of
future losses; availability of additional capital; lack of product
revenue; compliance with laws and regulations; difficulty
associated with research and development; risks associated with
clinical trials or studies; heightened regulatory scrutiny; early
stage product development; clinical trial risks; regulatory
approval processes; novelty of the psychedelic inspired medicines
industry; as well as those risk factors discussed or referred to
herein and the risks described in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2023, under
headings such as “Special Note Regarding Forward-Looking
Statements,” “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations,” and
other filings and furnishings made by the Company with the
securities regulatory authorities in all provinces and territories
of Canada which are available under the Company’s profile on SEDAR+
at www.sedarplus.ca and with the U.S. Securities and Exchange
Commission on EDGAR at www.sec.gov. Except as required by law, the
Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509733055/en/
For Media Inquiries, please contact: media@mindmed.co For
Investor Inquiries, please contact: ir@mindmed.co For Medical
Inquiries, please contact: medaffairs@mindmed.co
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Gen 2024 a Gen 2025